Acusphere focuses on developing proprietary drugs that offer significant benefits such as improved safety and efficacy, increased patient compliance, greater ease of use, expanded indications, or reduced cost. Their lead product candidate, Imagify, is a cardiovascular drug for the detection of coronary artery disease. Acusphere's technology allows them to control the porosity and size of nanoparticles and microspheres, enabling customization to address the delivery needs of various drugs. They are also developing other drugs using this technology, including AI-525 for acute pain, AI-850 for oncology, and AI-128 for asthma. Acusphere has sold AI-525 and AI-850 to Cephalon and collaborated with Elan on the development of AI-128. Their technology has the potential to create a wide variety of new drugs by reformulating hydrophobic drugs and creating sustained release formulations of existing drugs.